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Abstract
Light-activatable (“caged”) proteins have been used to correlate, with exquisite temporal and spatial
control, intracellular biochemical action with global cellular behavior. However, the chemical or
genetic construction of caged proteins is nontrivial, with subsequent laborious introduction into living
cells, potentially problematic competition with natural endogenous counterparts, and challenging
intracellular incorporation at levels equivalent to the natural enzymes. We describe the design,
synthesis, and characterization of small molecular equivalents of a caged Src kinase. These
compounds are easy to prepare and function by inhibiting the action of the natural unmodified
enzyme.
Protein kinases serve as key participants in signaling pathways by catalyzing phosphoryl
transfer from ATP to the serine, threonine, and/or tyrosine residues of protein substrates. The
eventual cellular response to a stimulus is often dependent upon when and where a particular
kinase is activated within the cell. Consequently, the use of constitutively active protein
kinases, or various defective mutants thereof, can only partly address the relationship between
the action of specific signaling enzymes and ensuing cellular behavior. The creation of “caged”
protein kinases, enzymes whose activities can be rapidly unleashed upon exposure to light, has
been reported.1 The photo-stimulation of caged proteins inside living cells has also been
described, which provides exquisite control over where and when the enzyme is activated.2
However, there are many challenges associated with the application of caged proteins3 to
cellular systems. First, chemically modified proteins are primarily introduced into cells via
microinjection, a process that limits subsequent behavioral studies to single cell analysis.
Second, enzymes often suffer a series of posttranslational modifications during their
intracellular lifetime. These modifications can be difficult to replicate in large-scale bacterial
enzyme preparations, which are often necessary for the acquisition of sufficient quantities for
caging experiments. Third, the intracellular introduction of unnatural enzymes, whether by
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of the wild type enzyme. Finally, the action of the caged protein might be difficult to interpret
in the presence of its natural intracellular counterpart. We describe a conceptually different
strategy for the acquisition of light-activated enzymes, an approach that targets the endogenous
enzyme and therefore has the potential to circumvent the limitations outlined above.
We recently reported the design and construction of a potent peptide-derived inhibitor 1 (Ki =
26 ± 4 nM; IC50 = 36 ± 2 nM) for the Src tyrosine kinase.4 Src is comprised of 3 domains,
which play various roles in catalysis (SH1), regulation (SH2 and SH3), or substrate recognition
(SH1, SH2 and SH3) (Figure 1).5 Compound 1, a “bivalent” species, simultaneously associates
with the active site (SH1 domain) and the SH2 domain. A key feature of the inhibitor is that
the SH1- and SH2-directed components, which are linked via a β-Ala tether, exhibit
approximately equal affinities for their respective binding sites on the target protein. The latter
property furnishes an inhibitor with a Src kinase affinity that significantly exceeds (∼50-fold)
the affinities of the individual components alone (e.g. SH1 domain-targeted monovalent
inhibitor 2; IC50 = 1.9 ± 0.3 μM) (Table 1).4 We reasoned that a bivalent inhibitor, containing
a photolabile site positioned at or near the β-Ala tether, would retain its ability to inhibit the
target enzyme (Figure 1). However, photolysis should split the inhibitor and thereby curtail its
effectiveness. Such a photodeactivatable inhibitor, which is functionally equivalent to a
photoactivatable Src kinase, can potentially address the challenges associated with caged
proteins outlined above.
We prepared a small collection of bivalent inhibitors (Table 1), each of which contains one of
three different photocleavable groups (I - III). In order to ensure the release of enzymatic
activity upon photolysis, the bivalent analog must be a potent inhibitor relative to compound
2. The photocleavable group III furnished the most powerful pre-photolysis inhibitor (6) in
the series 4 – 6. We also synthesized several peptides that have two photocleavable sites (8 -
10) using, as a guiding principle, the notion that double photolytic cleavage should destroy all
inhibitory activity. Unfortunately, these compounds proved to be exceedingly poor inhibitors.
Presumably the additional photosensitive site disrupts SH1 binding (8 – 9) and/or SH2 targeting
(8 - 10). With these features in mind, 6 was selected for further study.
We first addressed whether 6 simultaneously associates with the active site and SH2 regions
as envisioned (Fig. 1). Ac-pTyrGluGluIle-amide is a validated SH2 domain ligand with a
KD of 1 – 5 μM.6 Inhibitory efficacy of 6 is progressively and significantly compromised as a
function of SH2 ligand concentration (e.g. IC50 = 325 ± 60 nM @ 320 μM Ac-pTyrGluGluIle-
amide), the expected result for an SH2 domain-dependent, active site-targeted inhibitor
(Supporting Information).
Src kinase activity is completely blocked in the presence of 1.9 μM 6 (Fig. 2). Photolysis of
compound 6 releases kinase activity as measured by a previously described real time
fluorescence assay.7 Furthermore, longer photolysis times generate higher rates of substrate
phosphorylation. This response is precisely analogous to the direct photoactivation of a “caged”
enzyme, in which a photocleavable moiety is removed from a key residue required for activity.
In both instances, enhanced photolysis times create larger quantities of active enzyme. Under
optimized conditions, photolysis restores up to 90% of the activity displayed by Src in the
presence of compound 2 (1.9 μM; i.e. the by-product of photolysis) or up to 50% of Src activity
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in the absence of compound 2 (Supporting Information). These results compare favorably with
those obtained for previously described caged protein kinases1 and phosphatases8. An
analogous series of experiments were performed using lysates from COS-1 cell overexpressing
wild type Src kinase (Supporting Information).
Light-mediated activation of caged inhibitors, activators, and enzymes allows the investigator
to control when the agent of interest is switched on. In addition, light exposure time, intensity,
or the number of laser pulses, provides a means to control the amount of active species
generated. By contrast, spatial control of activity (i.e. localized release) via spot illumination
is generally reserved for high molecular weight species with slow diffusion rates, such as
proteins.2 Small molecules are unlikely candidates for experimentally meaningful localized
release since they commonly exhibit high diffusion rates. Nevertheless, small molecules can
be rendered slowly diffusible via anchoring to relatively immobile substrates (e.g. proteins,
organelles, etc) using targeting substituents (e.g. amino acid sequences, fatty acids, etc). With
this in mind, we explored the following question: can an analog of 6 be spatially affixed to a
high molecular object and still function in a light-sensitive fashion?
Bivalent peptide 11, which contains a Cys-for-βAla substitution in the tether region, serves as
an effective Src kinase inhibitor (Table 1). Compound 11 was covalently attached to Pierce
UltraLink® beads and incubated with varying concentrations of Src kinase to generate a
standard binding curve (Supporting Information). Illumination affords approximately 50%
non-bound active enzyme as assessed by two criteria. First, photolysis affords 45 ± 4 % Src
kinase activity in the supernatent (i.e. following removal of beads), as assessed using a real
time fluorescence assay (Supporting Information). Second, 50 ± 4% of Src kinase is physically
retained by the beads following photolysis (i.e. 50% is present in solution), as determined by
fluorescent imaging (Fig. 2). These results are consistent with solution studies described above
and support the notion that protein activity and location can be controlled with light using
appropriately designed inhibitory species. Application to cell-based systems is underway.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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A Photocleavable Caged Protein Equivalent.
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Enzymatic activity (ΔF vs time) as a function of irradiation time of compound 6 (1.9 μM).
Assays were performed as previously described.7 Experimental conditions: A (0 min hv), B
(2 min hv), C (15 min hv), D (120 min hv), and E (0 min hv + 1.9 μM compound 2).
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Presence of Src kinase on (A) nonirradiated and (B) irradiated UltraLink® beads modified with
bivalent inhibitor 11 as assessed by exposure to an Alexa Fluo488-labeled monoclonal Src
antibody.
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Table 1
Stable (1-2) and Photolytically Sensitive (4 – 11) Src Inhibitors.
# Peptide IC50(nM)
1 Ba-EEEIFGEF-Dap(Hna)-βA3-pYEEIEX
a 35 ± 2
2 Ba-EEEIFGEF-Dap(Hna)X + AcpYEEIE-NH2 (3) 1900
4 Ba-EEEIFGEF-Dap(Hna)-βA-I-βA-pYEEIEX 115 ± 9
5 Ba-EEEIFGEF-Dap(Hna)-βA-II-βA-pYEEIEX 38 ± 4
6 Ba-EEEIFGEF-Dap(Hna)-βA-III-βA-pYEEIEX 18 ± 5




11 Ba-EEEIFGEF-Dap(Hna)C-III-βA-pYEEIE-NH2 56 ± 4
a
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